Peptide Comparison
PancragenvsLivagen
Tetrapeptide bioregulator (Lys-Glu-Asp-Trp) that binds ACCT sequences in pancreatic gene promoters with 3-fold greater affinity than related peptides, stimulates beta-cell differentiation through Pdx1/Pax6/NGN3 transcription factor activation, and corrects impaired glucose tolerance in primates more physiologically than glimepiride
Tetrapeptide bioregulator (Lys-Glu-Asp-Ala) that directly penetrates cell nuclei and binds double-stranded DNA to induce chromatin decondensation in senescent lymphocytes, activate ribosomal genes, inhibit enkephalin-degrading enzymes with an IC50 of 20 μM, and restore protein synthesis capacity in aging cells through selective epigenetic remodeling
At a Glance
Quick
comparison
Dose Range
Pancragen
50–500 mcg
Livagen
2–10 mg
Frequency
Pancragen
Multiple times daily
Livagen
Once daily
Administration
Pancragen
Intramuscular injection
Livagen
Intramuscular injection
Cycle Length
Pancragen
8-12 weeks
Livagen
8-12 weeks
Onset Speed
Pancragen
Gradual (3-4 weeks)
Livagen
Gradual (3-4 weeks)
Evidence Level
Pancragen
Limited human trials
Livagen
Limited human trials
Efficacy
Benefit
ratings
Blood Sugar Balance
Pancreas Protection
Metabolic Aging Support
Cell Renewal
Liver Support
DNA Protection
Technical Data
Compound
specifications
Pancragen
Molecular Formula
C26H36N6O9
Molecular Weight
576.6 g/mol
Half-Life
Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic modifications to pancreatic gene expression (primate studies showed partial effects 3 weeks post-treatment); metabolized to constituent amino acids
Bioavailability
Demonstrated efficacy with both oral (Pankragen-Forte capsules) and intramuscular routes; penetrates cell membranes and nuclear membranes to reach DNA promoter regions; oral bioavailability sufficient for clinical effects at 500 mcg doses
CAS Number
Not definitively assigned
Livagen
Molecular Formula
C18H31N5O9
Molecular Weight
461.5 g/mol
Half-Life
Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic chromatin remodeling modifications; metabolized to constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
Bioavailability
Resistant to intestinal proteolysis when administered orally (weakly hydrolyzed by intestinal peptidases); efficient absorption from intramuscular injection sites; penetrates cytoplasmic and nuclear membranes to reach cell nuclei and nucleoli
CAS Number
Not assigned (research compound)
Protocols
Dosing
tiers
Pancragen
Livagen
Applications
Best
suited for
Pancragen
Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
Pancragen is particularly well-suited for individuals focused on supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
Pancragen is particularly well-suited for individuals focused on geroprotective pancreatic support to maintain beta-cell differentiation and insulin production. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting metabolic aging
Pancragen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting metabolic aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance
Pancragen is particularly well-suited for individuals focused on adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Livagen
Comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells
Livagen is particularly well-suited for individuals focused on comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting liver function and hepatoprotection in the context of aging
Livagen is particularly well-suited for individuals focused on supporting liver function and hepatoprotection in the context of aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Restoring protein synthesis and ribosomal function in elderly individuals
Livagen is particularly well-suited for individuals focused on restoring protein synthesis and ribosomal function in elderly individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Khavinson bioregulator protocols for anti-aging and longevity
Livagen is particularly well-suited for individuals focused on khavinson bioregulator protocols for anti-aging and longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Pancragen
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Minor digestive changes
Uncommon
- Mild hypoglycemia
Serious
- No documented serious adverse effects
Livagen
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Digestive enzyme changes
Uncommon
- Transient flu-like symptoms
Serious
- No documented serious adverse effects
Research Status
Safety
& evidence
Pancragen
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Pancragen shows favorable safety profile in preclinical toxicology studies with no serious adverse events at therapeutic doses. As a multi-peptide complex derived from pancreatic tissue, potential allergenicity risk exists in porcine-sensitive individuals. Gastrointestinal tolerance is excellent when taken orally. Limited human clinical data; primarily used in clinical practice in Central/Eastern Europe with reported safety in observational studies.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, tryptophan)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive hypoglycemia or insulin-secreting tumors (insulinoma) — Pancragen's beta-cell stimulating effects may exacerbate hypoglycemia
- xConcurrent use of sulfonylureas without medical supervision — potential for additive hypoglycemic effects
Livagen
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Livagen (a liver-derived peptide extract) carries a safety profile established through decades of use in Eastern European hepatology and gastroenterology clinics. As an organ-derived extract rather than a synthetic single peptide, it contains multiple bioactive components promoting hepatocyte regeneration and cytoprotection. Adverse events are minimal in reported clinical experience—mild gastrointestinal upset occurring in <5% of patients. The compound shows no hepatotoxicity, nephrotoxicity, or immunosensitization in available safety surveillance data from thousands of patients.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive autoimmune conditions in flare without physician supervision
- xConcurrent use of opioid medications — Livagen's enkephalinase inhibition may alter opioid metabolism
Decision Guide
Which is
right for you?
Choose Pancragen if...
- Supporting pancreatic function and glucose metabolism in aging individuals with prediabetic tendencies
- Geroprotective pancreatic support to maintain beta-cell differentiation and insulin production
- Comprehensive Khavinson bioregulator protocols targeting metabolic aging
- Adjunctive metabolic support alongside lifestyle interventions for age-related glucose intolerance
Choose Livagen if...
- Comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells
- Supporting liver function and hepatoprotection in the context of aging
- Restoring protein synthesis and ribosomal function in elderly individuals
- Khavinson bioregulator protocols for anti-aging and longevity